International Experts To Present On Avita Medical ‘s Regenerative Medicine Approach At Medical Symposium, London

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - April 22, 2016) - Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in the treatment of wounds and skin defects, today announced that Mr Paul Hayes, Vascular Surgeon at Addenbrooke’s Hospital, UK and Mr Harvey Chant, Vascular Surgeon, The Royal Cornwall Hospital, UK will present on their experience and data on the use of Avita’s ReGenerCell™ in wound care at the Charing Cross International Symposium at Olympia Grand, London, UK from 26-29 April. This year’s programme will focus on the challenges in the vascular and endovascular field.

Details of the sessions are as follows:

The Use of Autologous Cell Suspension for Complex Diabetic Wounds
Presenter: Mr Harvey Chant
Session type: Mini-symposium: Wound Healing
Location: Upper Main Auditorium
Date: Tuesday 26 April
Time: 17.16 - 17.24

A Pilot Randomised Controlled Trial of ReGenerCell™ for the Treatment of Venous Leg Ulcers
Presenter: Mr Paul Hayes
Session type: C Innovation Showcase
Location: Olympia Room
Date: Wednesday 27 April
Time: 13.40 - 13.50

The Use of Autologous Cell Suspension in Wound Healing
Presenter: Mr Harvey Chant
Session type: CX ilegx Collaboration Day
Location: Pillar Hall
Date: Thursday 28 April
Time: 08.52 - 09.30

ABOUT CHARING CROSS SYMPOSIUM

The Charing Cross Symposium first took place in 1978 at Charing Cross Hospital, Hammersmith, London, and is the longest running vascular and endovascular symposium in Europe and one of the largest in the world.

This year’s symposium focuses on challenges in complete optimal vascular disease management, catering for all vascular specialists.

For further information, visit: www.cxsymposium.com

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient’s own skin. The Company’s regenerative product portfolio includes ReCell® for burns aimed at plastic reconstructive procedures, ReGenerCell™ for chronic wounds and ReNovaCell™ of restoration of pigmentation and cosmesis. ReCell®, ReGenerCell™ and ReNovaCell™ are patented, CE-marked for Europe. ReCell® is TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. trial is well underway aimed at securing FDA approval.

To learn more, visit www.avitamedical.com.